A retrospective study of enoxaparin, rivaroxaban, or apixaban for reducing the risk of developing venous thromboembolism (VTE)
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Apixaban (Primary) ; Enoxaparin sodium (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- 27 Oct 2021 New trial record
- 13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association.